April 2009 Volume 5 Number 4
Visit Nature Reviews Rheumatology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=39&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Rheumatology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=25&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=42&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
*********************************************************************
Nature Reviews Rheumatology Impact Factor: 3.812*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
"Officially endorsed by the Asia Pacific League of Associations for
Rheumatology"
=========================== ADVERTISEMENT ===========================
From April 2009, the Nature Clinical Practice journals will be renamed
Nature Reviews.
Nature Clinical Practice Rheumatology has been completely redesigned
and is now called Nature Reviews Rheumatology to bring all the qualities
of this top-ranked* life science review series to the clinical sciences.
For more information visit:
http://links.ealert.nature.com/ctt?kn=11&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Bias, conflict of interest and publishing
Peter E. Lipsky
p175 | doi:10.1038/nrrheum.2009.52
http://links.ealert.nature.com/ctt?kn=37&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Connective tissue diseases: Undoing the damage caused by systemic sclerosis
p177 | doi:10.1038/nrrheum.2009.56
http://links.ealert.nature.com/ctt?kn=104&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
IN BRIEF
Bone diseases | Autoimmunity | Experimental arthritis | Rheumatoid arthritis
p178 | doi:10.1038/nrrheum.2009.44
http://links.ealert.nature.com/ctt?kn=67&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Rheumatoid arthritis: Predicting RA progression
p178 | doi:10.1038/nrrheum.2009.57
http://links.ealert.nature.com/ctt?kn=106&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Experimental arthritis: Exploiting IL-6 trans signaling targets
collagen-induced arthritis
p179 | doi:10.1038/nrrheum.2009.58
http://links.ealert.nature.com/ctt?kn=24&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Rheumatoid arthritis: Anti-MCV antibodies-a promising new biomarker for RA
p179 | doi:10.1038/nrrheum.2009.59
http://links.ealert.nature.com/ctt?kn=2&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
IL-3 prevents inflammatory arthritis
p180 | doi:10.1038/nrrheum.2009.60
http://links.ealert.nature.com/ctt?kn=92&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Rheumatoid arthritis: Do steroids increase metabolic syndrome risk?
p180 | doi:10.1038/nrrheum.2009.61
http://links.ealert.nature.com/ctt?kn=91&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
IN BRIEF
Autoimmunity | Rheumatoid arthritis | Experimental arthritis |
Spondyloarthropathies
p181 | doi:10.1038/nrrheum.2009.45
http://links.ealert.nature.com/ctt?kn=70&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Inflammation: SIGN here for anti-inflammatory activity!
p181 | doi:10.1038/nrrheum.2009.62
http://links.ealert.nature.com/ctt?kn=18&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Connective tissue diseases: Autoantibody profiles linked to ethnicity
in pediatric SLE
p182 | doi:10.1038/nrrheum.2009.32
http://links.ealert.nature.com/ctt?kn=100&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Rheumatoid arthritis: PlGF's role extends beyond angiogenesis
p182 | doi:10.1038/nrrheum.2009.35
http://links.ealert.nature.com/ctt?kn=45&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Vasculitis syndromes: Vasculitis therapy-between Scylla and Charybdis
Richard Watts
p183 | doi:10.1038/nrrheum.2009.46
Achieving effective maintenance therapy with minimal adverse effects for
patients with antineutrophil cytoplasmic autoantibody associated vasculitis
is a major challenge facing the vasculitis community. A study by Pagnoux
et al. shows that azathioprine and methotrexate have similar efficacy and
adverse event profiles when used for remission maintenance in these patients.
http://links.ealert.nature.com/ctt?kn=52&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Therapy: Are TNF inhibitors safe in pregnancy?
Monika Ostensen
p184 | doi:10.1038/nrrheum.2009.47
Tumor necrosis factor inhibitors are fast acting, highly effective and
well tolerated by the majority of patients, but their safety in pregnant
women remains a matter of debate. The latest research weighs in on the
issue.
http://links.ealert.nature.com/ctt?kn=54&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Therapy: Methotrexate guidelines: compromise to reach consensus
Joel M. Kremer
p186 | doi:10.1038/nrrheum.2009.41
Practice in relation to administration of methotrexate varies considerably
despite its prominent place in the treatment arsenal for various rheumatic
diseases. A multinational initiative has developed recommendations, based
on the literature and in consultation with a large panel of rheumatologists,
for use of this drug.
http://links.ealert.nature.com/ctt?kn=5&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Genetics: Unraveling the genetics of autoimmune disease
Timothy J. Vyse
p187 | doi:10.1038/nrrheum.2009.42
The ability to conduct genetic association studies on a genome-wide scale
has revolutionized approaches to reveal the genetic basis of autoimmune
diseases. A comparison by Zhernakova and colleagues of the known
susceptibility genes in 11 immune-related diseases reveals evidence for
shared gene effects and common pathogenetic mechanisms.
http://links.ealert.nature.com/ctt?kn=21&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Fibromyalgia: A new treatment option for fibromyalgia
Robert M. Bennett
p188 | doi:10.1038/nrrheum.2009.48
The FDA's approval of milnacipran reflects advances in the development
of drugs aimed at modulating pain circuitry in fibromyalgia.
http://links.ealert.nature.com/ctt?kn=103&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
A symptom-based approach to pharmacologic management of fibromyalgia
Chad S. Boomershine and Leslie J. Crofford
p191 | doi:10.1038/nrrheum.2009.25
In the context of a multidisciplinary approach to the management of
fibromyalgia, guidelines recommend that pharmacologic therapies be
individually tailored to a patient's symptoms but do not offer a method
of assessment. In this Review, the authors provide a rapid,
easily-remembered framework for the quantitation and pharmacologic
management of symptoms that is suitable for use in a busy clinical practice.
Abstract: http://links.ealert.nature.com/ctt?kn=68&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=87&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Transforming growth factor [beta] as a therapeutic target in systemic sclerosis
John Varga and Boris Pasche
p200 | doi:10.1038/nrrheum.2009.26
In patients with systemic sclerosis, impaired activity of transforming
growth factor [beta] (TGF-[beta]) has a central role in the pathogenesis
of fibrosis, which leads to the progression of the disease and severe
organ damage. In this context, the authors discuss the mechanisms of
aberrant TGF-[beta] signaling and highlight the potential of TGF-[beta]
as a therapeutic target in systemic sclerosis.
Abstract: http://links.ealert.nature.com/ctt?kn=66&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=93&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Management of cardiovascular disease risk in chronic inflammatory disorders
Mariana J. Kaplan
p208 | doi:10.1038/nrrheum.2009.29
A wealth of evidence suggests that the prevalence of cardiovascular disease
is increased in patients suffering from chronic inflammatory disorders,
particularly rheumatoid arthritis and systemic lupus erythematosus, as
discussed in this Review. In the absence of specific guidelines, Dr Kaplan
highlights strategies for the prevention and treatment of cardiovascular
events in patients with chronic inflammatory disease.
Abstract: http://links.ealert.nature.com/ctt?kn=38&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=32&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Periodontitis in systemic rheumatic diseases
Paola de Pablo, Iain L. C. Chapple, Christopher D. Buckley and Thomas
Dietrich
p218 | doi:10.1038/nrrheum.2009.28
A potential association between periodontitis, a chronic inflammatory
disease characterized by loss of the periodontal ligament and alveolar
bone, and systemic rheumatic diseases-particularly rheumatoid
arthritis-has been suggested. Results from studies that support such a
link are outlined in this article, as are causal and non-causal factors
that could determine an association between the two conditions.
Abstract: http://links.ealert.nature.com/ctt?kn=72&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=17&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Rapidly progressive fatal interstitial lung disease in a patient with
systemic sclerosis
Kristine Phillips, Cathryn Byrne-Dugan, Eric Batterson and James R. Seibold
p225 | doi:10.1038/nrrheum.2009.30
Interstitial lung disease is a common manifestation of systemic sclerosis,
and often leads to death in these patients. These authors describe the
case of a previously healthy woman with acute systemic sclerosis who
experienced an unusually fulminant course of interstitial lung disease,
which did not respond to treatment with intravenous cyclophosphamide.
Abstract: http://links.ealert.nature.com/ctt?kn=50&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=7&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
The cholinergic anti-inflammatory pathway: towards innovative treatment
of rheumatoid arthritis
Marjolein A. van Maanen, Margriet J. Vervoordeldonk and Paul P. Tak
p229 | doi:10.1038/nrrheum.2009.31
Evidence is mounting that the cholinergic pathway is involved in the
pathogenesis of rheumatoid arthritis and other immune-mediated inflammatory
disorders. This timely article provides an overview of the role of the vagus
nerve and [alpha]7 nicotinic acetylcholine receptor in this pathway, and
highlights novel strategies that could exploit these targets in the
treatment of rheumatic diseases.
Abstract: http://links.ealert.nature.com/ctt?kn=86&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=49&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Immunology
FOCUS ON IMMUNE SIGNALING CROSS-TALK
Nature Immunology presents a series of specially commissioned articles
that focus on the molecular basis for and biological consequences of
the interplay among signaling pathways. The web focus also includes
highlights of recent research findings and several short
comments-written by experts-providing in-depth insight into specific
signaling cross-talk points.
For more information, visit
http://links.ealert.nature.com/ctt?kn=15&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=14&m=32242286&r=MTc2NDQ4MTc5OAS2&b=2&j=NDcwNTIwOTgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
